ClinicalTrials.gg
RecruitingNCT07019493Updated Apr 21, 2026

Young Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke

An observational study in Stroke Patients, Stroke and Stroke; Sequelae, sponsored by The Florey Institute of Neuroscience and Mental Health. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by The Florey Institute of Neuroscience and Mental Health · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Stroke with a site in Australia — 22 open to participants now, 29 under way, 11 of them phase 3. Stroke · Australia.

Planned enrollment
12th of 13
100 · median 626
Started
2025
with 7 others
Observational
13 of 122
3 open now
Primary completion
2026-12
later than 9 of 28 live
Registered
117th of 122
by date

Among the 122 studies in Stroke with a site in Australia, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2025, is one of 13 observational ones, reaches primary completion later than 9 of the 28 other live ones, and was the 117th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

22 of the 122 studies in Stroke with a site in Australia are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Stroke with a site in Australia, or all of them as a file.
02

Study summary

The Investigators are running a small, early-phase research study across several hospitals in Melbourne, Australia. The study will involve up to 100 young adults between the ages of 18 and 55 who have had a stroke. The goal is to test how practical it is to carry out a detailed health assessment process-called "deep phenotyping"-with this group.

This process involves collecting a wide range of information and samples from stroke survivors to better understand each participant's condition. The Investigators will look at how well this approach works in practice, including how easy it is to use, whether it's done consistently, and how acceptable it is to participants.

At the same time, the Investigators will also explore how different factors-such as biological markers (biomarkers), age, sex, type of stroke, lifestyle, and environment-might be related to stroke recovery. This pilot study will prepare for larger studies in the future.

03

Conditions studied

  • Stroke Patients
  • Stroke
  • Stroke; Sequelae
  • Young Adults

Keywords

  • recovery
  • young stroke
  • ischemic stroke
  • hemorrhagic stroke
  • poststroke fatigue
  • post-stroke cognitive impairment
  • function
  • mood
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Young adult stroke survivors within 3 months of stroke

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 18 and 55 years.
  2. Within one month of acute stroke confirmed with standard of care brain imaging or clinical diagnosis or for those for whom recruitment \<1 month of stroke is not possible they may be recruited to participate within 3-months of stroke

Exclusion criteria

Exclusion Criteria:

  1. Severe, intercurrent or progressive illness likely to EITHER

    1. Have a prognosis for survival under 24 months; OR
    2. In the opinion of the investigator will mask the importance to the individual participant data (e.g. severe MS, dementia, etc)
  2. Major psychiatric condition requiring medical intervention
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Young adult stroke survivors (age 18 to 55 inclusive)

    Other: Observational Cohort

Interventions

  • OtherObservational Cohort

    The deep phenotyping observational study observes young adult stroke recovery trajectories and will also explore potential recovery biomarkers via: advanced MRI imaging; samples including blood, saliva, urine and hair stored for future analysis that may include (but is not limited to) proteomics, genomics and cortisol; and, a PET scan sub study involving \~20 participants (additional inclusion criteria) exploring the association of reactive astrogliosis with recovery outcomes using the experimental Positron Emission Tomography 18F-SMBT-1 tracer (AU TGA CTN in place). Associations with personal and environmental factors including: physical activity and sleep quality via device (Actigraph and Somfit) and self-report; exposures such as home and work environments, diet, socioeconomic status, and dental health; quality of life, resilience, and locus of control. Monitor healthcare utilisation, changes in medication and medical condition, participant experience and response to the assessments.

    Also known as: Deep phenotyping

06

What researchers measure

Primary outcomes

  1. Implementability (feasibility, fidelity and acceptability)

    Evaluation of the implementability will include assessment of the protocol's: * Feasibility, e.g. * Recruitment rate * Retention * Proportion of participants screened that enrolled * Safety via adverse events * Fidelity, e.g. * Proportion of assessments attended * Proportion of data collected and biobanked or analysed * Acceptability, e.g. o Participant acceptability surveys

    Time frame: From enrolment to the six month assessment visit

Secondary outcomes

  1. Fatigue Severity Scale

    FSS: A 9-item (or 7-item with the first two items removed) measure of fatigue impairment. Measured at baseline (\<1month post stroke), 3- and 6-months post stroke.

    Time frame: 6 months

  2. Visual Analogue Scale to Assess Fatigue (VAS-F)

    18-item visual analogue scale of fatigue and energy items.

    Time frame: Assessment at <1, 3- and 6-months post stroke

  3. Modified Fatigue Impact Scale (MFIS) is a multidimensional scale that reports physical, psychological and cognitive aspects of fatigue

    A multidimensional 21-item measure that evaluates physical, psychological and cognitive aspects of fatigue. Measured at baseline (\<1month post stroke), 3- and 6-months post stroke.

    Time frame: 6 months

  4. Cognitive Assessment

    Assessment to evaluate cognitive domains such as visuospatial memory, auditory verbal learning, visual attention, task switching, verbal fluency, and verbal short-term and working memory. Assessment \<1-month, 3- and 6-months post stroke.

    Time frame: 6 months

  5. modified Rankin Scale (mRS)

    Single-item evaluation of global disability. Assessed at \<1-month, 3- and 6-months post stroke

    Time frame: 6 months

  6. 10 metre walk test (10mWT)

    Gait assessment, evaluated \<1-month, 3- and 6-months post stroke

    Time frame: 6 months

  7. Visual Analogue Scale of the Impact of Fatigue on Communication Ability

    Visual analogue scale (0-10) assessing the impact of fatigue on communication ability. Measured at baseline (\<1month post stroke), 3- and 6-months post stroke.

    Time frame: 6 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Sharing of individual patient data will be considered upon reasonable request by qualified researchers with appropriate IRB/HREC approval

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 17 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 13, 2025
StartActual
Jul 19, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 2027
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019493
Lead sponsor
The Florey Institute of Neuroscience and Mental Health
Collaborators
University of Melbourne, University of Newcastle, Australia, Austin Health, La Trobe University, The Alfred
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jul 19, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 21, 2026

Study contacts

Emily Ramage, BPhysio, PhD
Contact
emily.ramage@florey.edu.au
+61 3 90357000
Marie Ferraro, BSc
Contact
marie.ferraro@student.unimelb.edu.au
+61390357000
Vincent Thijs, MD, PhD
principal investigator · The Florey Institute of Neuroscience and Mental Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion